ClinicalTrials.gg
Not yet recruitingNCT07688382Updated Jul 7, 2026

The Effect of Lavender Aromatherapy on Cognitive Function in Older Adults With Mild Cognitive Impairment

An interventional study of aromatherapy in MCI, sponsored by China Medical University, China. Not yet recruiting. Open to participants aged 60 Years to 95 Years. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by China Medical University, China · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
60 Years to 95 Years
Sex
All
01

Study summary

  1. To analyze the therapeutic effects of lavender aromatherapy on memory function and overall cognitive function in older adults with Mild Cognitive Impairment (MCI);
  2. To analyze whether lavender aromatherapy improves executive function, language ability, attention, visuospatial ability, anxiety, depression, quality of life, and sleep in older adults with MCI.
Read the detailed description

The intervention protocol was established as follows: Based on the elderly participant's usual bedtime, the time of going to bed was recorded. The participant was instructed to assume a comfortable sleeping position, use the graduated dropper provided with the essential oil bottle to measure 0.15 ml (approximately 3 drops; theoretically, 0.05 ml per drop) of diluted lavender essential oil, and drip it vertically onto the upper center of a cotton pad. The cotton pad was then pinned to the collar with a safety pin, and the participant was instructed to inhale the scent evenly for 30 minutes. Afterward, the intervention staff or caregiver will remove the cotton pad. The intervention will be conducted 5 days a week for 12 weeks.

02

Conditions studied

  • MCI
03

In context

Lead sponsor

China Medical University, China is the lead sponsor of 94 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The MCI mentioned in this study meets the diagnostic criteria proposed by the *Chinese Expert Consensus on the Diagnosis and Treatment of Alzheimer's Disease-Derived Mild Cognitive Impairment (2021)*: cognitive impairment reported by the patient or an informant, or identified by an experienced clinician; objective evidence of impairment in one or more cognitive domains, with episodic memory impairment being the most common; complex instrumental activities of daily living may be mildly impaired, but the ability to perform basic activities of daily living remains independent; the diagnostic criteria for dementia are not met.
  2. -Beijing version scores were adjusted for education level: ≤13 for junior high school education or below, ≤19 for high school education, and ≤24 for university education or above; MMSE score >24; ADL score \<23.
  3. Age between 60 and 79 years.
  4. Normal olfactory function assessed using the "Sniffin' Sticks" test.
  5. Ability to communicate normally and complete cognitive assessments.
  6. Residing in a senior care facility with no plans to leave within the next 12 weeks.

Exclusion criteria

Exclusion Criteria:

  1. Presence of other conditions known to affect cognitive function, such as psychiatric disorders (e.g., schizophrenia, depression).
  2. History of asthma or any allergic conditions.
  3. Use of any prescription medications that may impact cognitive function (including psychotropic drugs and others)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
70 participants (estimated)

Study arms

  • Other
    Aromatherapy experimental group

    Aromatherapy experimental group : Aromatherapy The aromatherapy intervention protocol is as follows: Based on the elderly participant's usual bedtime, record the time they go to bed; instruct them to assume a comfortable sleeping position; using the graduated dropper provided with the essential oil bottle, dispense 0.15 ml (approximately 3 drops; theoretically, 0.05 ml per drop) of diluted lavender essential oil and drip it vertically onto the upper center of a cotton pad; pin the cotton pad to the collar with a safety pin; and have the participant inhale the scent evenly for 30 minutes. Afterward, the intervention staff or caregiver will remove the cotton pad. The intervention will be conducted 5 days a week for 12 weeks.

    Other: aromatherapy

  • No intervention
    Control group

    no-treatment control group receiving routine health education only

Interventions

  • Otheraromatherapy

    Participants in the intervention group will receive aromatherapy inhalation for 30 minutes per session, five times a week, over a period of 12 week

06

What researchers measure

Primary outcomes

  1. Gobal cognitive function

    Use the Mini-Mental State Examination to assess overall cognitive function.

    Time frame: Week 12

  2. Memory

    Use the Auditory Verbal Learning Test to assess memory function.

    Time frame: Week 12

Secondary outcomes

  1. Language function

    Use the Boston Naming Test to assess Language function

    Time frame: Week 12

  2. Executive function

    Use the TMT-B to assess Executive function

    Time frame: Week 12

  3. Visual space

    Use the Draw-a-Clock Test to assess Visual space

    Time frame: Week 12

  4. Attention

    Use the TMT-A to assess Attention

    Time frame: Week 12

  5. Anxiety

    Use the 15-item Geriatric Depression Scale to assess Anxiety

    Time frame: Week 12

  6. Depression

    Use the 15-item Geriatric Depression Scale to assess Depression

    Time frame: Week 12

  7. Sleep Quality

    Use the Pittsburgh Sleep Quality Index to assess Depression

    Time frame: Week 12

  8. Quality of Life assess

    Use the ShortForm 8 Health Survey Questionnaire to assess Depression

    Time frame: Week 12

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Jan 2027, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2026
First posted
Jul 7, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 2, 2027
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07688382
Lead sponsor
China Medical University, China
Responsible party
Yuxin Zhang (Student, China Medical University, China) — Principal investigator
First posted
Jul 7, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 2, 2027 (estimated)
Last update
Jul 7, 2026

Study contacts

Yuxin Zhang, Graduate
Contact
18867845231@163.com
18867845231
Yuxin Zhang, Graduate
principal investigator · China Medical University, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion